Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
Massana J, Moller HJ,
Burrows GD, Montenegro RM
Department of Psychiatry,
Hospital Clinico de Barcelona, Spain.
Int Clin Psychopharmacol 1999 Mar; 14(2):73-80
ABSTRACT
The aim of this study was to compare the efficacy and tolerability of reboxetine, a uniquely selective noradrenaline reuptake inhibitor, with the selective serotonin reuptake inhibitor, fluoxetine.
A double-blind, randomized, parallel-group, multicentre design was employed.
One hundred and sixty-eight patients with acute major depressive episodes were randomized to receive oral reboxetine (8-10 mg/day) or oral fluoxetine (20-40 mg/day).
The treatment period was 8 weeks. Reboxetine and fluoxetine were similarly effective as assessed by the mean reduction in total Hamilton Depression Rating Scale score, the percentage of responders and patients in remission, Clinical Global Impression severity of illness and global improvement scores and Montgomery-Asberg Depression Rating Scale.
A sub-analysis of patients with severe depression indicated that reboxetine had superior efficacy compared with fluoxetine.
Both treatments resulted in some improvement in Social Adaptation Self-evaluation Scale total scores and this was more evident for those patients treated with reboxetine who achieved remission.
Both treatments were well tolerated. The results indicate that reboxetine is an effective and well tolerated antidepressant, being more effective than fluoxetine in patients with severe depression, and more effective in terms of social functioning in those patients who achieved remission.
Reboxetine research
/ abstracts
1. Reboxetine
role in antidepressant therapy
2. Reboxetine
efficacy and tolerability
3. Reboxetine
clinical
pharmacologic profile
4. Inhibiting
the reuptake of noradrenaline and serotonin
5. Reboxetine
and depression in the elderly
6. Reboxetine
with severe major depressive disorder
7. Reboxetine
clinical
efficacy in major depression
8. Reboxetine
tolerability
and safety for major depression
9. Reboxetine
comparison with fluoxetine
10 Reboxetine
versus fluoxetine, impact on social functioning
11. Reboxetine versus
fluoxetine, differential effects
12. Reboxetine
prevents relapse in major depression
13 Reboxetine
efficacy compared with imipramine
14. Noradrenaline
reuptake inhibition
15. Antidepressants
noradrenergic
versus serotonergic
16. Reboxetine
in the treatment of bulimia
17.
Reboxetine
hemodynamic effects in healthy males
18. Reboxetine
effects of antidepressant therapy
19. Reboxetine
place in antidepressant
therapy
20. Reboxetine
stimulant effects in patients with narcolepsy
21. Reboxetine
selective noradrenaline reuptake inhibitor (NARI)
